Published in Mayo Clin Proc on January 01, 1996
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest (1997) 1.76
Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev (2012) 1.68
Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis (2013) 1.23
Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) (2012) 1.21
Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev (2004) 1.19
Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care (2008) 1.18
Pneumocystis carinii cell wall biosynthesis kinase gene CBK1 is an environmentally responsive gene that complements cell wall defects of cbk-deficient yeast. Infect Immun (2004) 1.15
PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol (1997) 1.03
The immunology of parasite infections in immunocompromised hosts. Parasite Immunol (2006) 1.01
Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med (2011) 1.00
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther (2009) 0.99
An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer (2005) 0.97
Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis (2014) 0.92
Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia--a case-control study. BMC Infect Dis (2002) 0.91
Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis (2006) 0.91
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun (2003) 0.91
The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis (2004) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest (1998) 0.89
Pneumonia severity index in the immunocompromised. Can Respir J (2006) 0.88
Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice. Infect Immun (1999) 0.87
The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther (2014) 0.87
Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis (2004) 0.87
Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series. Arthritis Care Res (Hoboken) (2011) 0.84
Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations. Clin Med Insights Circ Respir Pulm Med (2015) 0.84
Glycosphingolipids mediate pneumocystis cell wall β-glucan activation of the IL-23/IL-17 axis in human dendritic cells. Am J Respir Cell Mol Biol (2012) 0.84
Pneumocystis jiroveci Pneumonia in an Atypical Host. Clin Breast Cancer (2011) 0.84
Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Res Ther (2011) 0.83
Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review. J Thorac Dis (2013) 0.83
Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. HIV AIDS (Auckl) (2010) 0.82
Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One (2014) 0.81
High-resolution CT of complications of idiopathic fibrotic lung disease. Br J Radiol (2011) 0.81
National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. PLoS One (2016) 0.81
Why the International Workshops on Opportunistic Protists? Eukaryot Cell (2009) 0.80
Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis (2011) 0.80
Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients. PLoS One (2015) 0.80
Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther (2014) 0.79
Glucocorticosteroid in treatment of severe pneumonia. Mediators Inflamm (2013) 0.79
Analysis of Pneumocystis carinii introns. Infect Immun (1999) 0.79
Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am (2015) 0.78
Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.78
Genetic variation at the mitochondrial large-subunit rRNA locus of Pneumocystis isolates from simian immunodeficiency virus-infected rhesus macaques. Clin Diagn Lab Immunol (2003) 0.78
Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc (1996) 0.78
Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak. Clin Med Insights Circ Respir Pulm Med (2015) 0.78
Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity? Multidiscip Respir Med (2012) 0.77
Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer. Oncol Lett (2012) 0.77
Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis. BMJ Case Rep (2013) 0.77
Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection. J Acquir Immune Defic Syndr (2014) 0.76
Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages. Inflammation (1997) 0.76
Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int (2008) 0.76
69-year-old woman with dyspnea and cough productive of white sputum. Mayo Clin Proc (2011) 0.75
Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther (2017) 0.75
SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs. PLoS One (2015) 0.75
Pneumocystis pneumonia during Postoperative Adjuvant Chemotherapy for Breast Cancer. Case Rep Oncol Med (2013) 0.75
Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients. J Clin Microbiol (2016) 0.75
Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. PLoS One (2016) 0.75
Intermittent Courses of Corticosteroids Also Present a Risk for Pneumocystis Pneumonia in Non-HIV Patients. Can Respir J (2016) 0.75
Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma. IDCases (2014) 0.75
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol (2016) 0.75
Reducing the risk of infection in a 74-year-old man who is to receive prednisone. CMAJ (2014) 0.75
Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review. Front Pediatr (2017) 0.75
[Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review]. Z Rheumatol (2006) 0.75
Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A (1991) 4.61
Pulmonary Langerhans'-cell histiocytosis. N Engl J Med (2000) 3.83
Stretch induces cytokine release by alveolar epithelial cells in vitro. Am J Physiol (1999) 1.89
Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture. J Clin Microbiol (2001) 1.69
Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol (2000) 1.39
Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol (1993) 1.38
Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest (1995) 1.24
Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect (1998) 1.18
Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun (1995) 1.18
Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem (2000) 1.17
Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components. Infect Immun (1994) 1.16
Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-alpha in response to Pneumocystis carinii. J Immunol (1994) 1.06
PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol (1997) 1.03
Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am J Respir Cell Mol Biol (1993) 1.02
Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med (1997) 1.00
Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue. Am J Respir Cell Mol Biol (1998) 0.99
Characterization of Pneumocystis carinii PHR1, a pH-regulated gene important for cell wall Integrity. J Bacteriol (2001) 0.96
Beta-glucan from Pneumocystis carinii stimulates TNF alpha release from alveolar macrophages. J Eukaryot Microbiol (1999) 0.95
Pneumocystis carinii uses a functional cdc13 B-type cyclin complex during its life cycle. Am J Respir Cell Mol Biol (2000) 0.95
Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation (1996) 0.94
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc (1999) 0.94
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. Eur Respir J (2005) 0.89
Alveolar macrophage interactions with Pneumocystis carinii. J Lab Clin Med (1999) 0.89
Fungal beta-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages. Infect Immun (1996) 0.87
Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol (2001) 0.87
Pneumocystis carinii induces ICAM-1 expression in lung epithelial cells through a TNF-alpha-mediated mechanism. Am J Physiol (1997) 0.86
Tissue localization of transforming growth factor-beta1 in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med (1996) 0.85
Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A. Am J Respir Cell Mol Biol (2001) 0.83
Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide. Immunol Lett (1993) 0.83
Drug-induced pulmonary disease. Semin Respir Infect (1995) 0.83
Lung extracellular matrix: physiology and pathophysiology. Hosp Pract (Off Ed) (1990) 0.82
Circulating transforming growth factor-beta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest (2001) 0.81
Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii. J Biol Chem (2001) 0.81
Characterization of a mitogen-activated protein kinase from Pneumocystis carinii. Am J Physiol (1998) 0.80
Pneumocystis carinii modulates cyclin-dependant kinase activity in a lung epithelial cell line. J Eukaryot Microbiol (1996) 0.79
Analysis of Pneumocystis carinii introns. Infect Immun (1999) 0.79
Pneumocystis carinii beta-glucan induces release of macrophage inflammatory protein-2 from primary rat alveolar epithelial cells via a receptor distinct from CD11b/CD18. J Eukaryot Microbiol (2001) 0.79
Analysis of a pheromone receptor and MAP kinase suggest a sexual replicative cycle in Pneumocystis carinii. J Eukaryot Microbiol (2001) 0.79
Identification of a cell division cycle (cdc2) homologue in Pneumocystis carinii. J Eukaryot Microbiol (1996) 0.78
Diagnosing ventilator-associated pneumonia: the role of bronchoscopy. Mayo Clin Proc (1994) 0.77
Assembly of cell wall glucans by Pneumocystis carinii: characterization of the Gsc-1 subunit mediating beta-glucan synthesis. J Eukaryot Microbiol (1999) 0.77
Adhesive glycoproteins in the pathogenesis of Pneumocystis carinii pneumonia: host defense or microbial offense? J Lab Clin Med (1995) 0.77
Mechanisms of defence in the lung: lessons from Pneumocystis carinii pneumonia. Sarcoidosis Vasc Diffuse Lung Dis (2000) 0.77
Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages. Inflammation (1997) 0.76
Diagnosis of Pneumocystis carinii pneumonia: does use of only bronchoalveolar lavage suffice? Mayo Clin Proc (1996) 0.75
Delayed pulmonary fibrosis after nitrosourea therapy. N Engl J Med (1990) 0.75
Fungal beta-glucan can yield false-positive results with the limulus amebocyte lysate endotoxin assay. Chest (1999) 0.75
Recognition of Pneumocystis carinii antigen on its surface by immunohistochemistry and immunoelectron microscopy. J Korean Med Sci (1998) 0.75
Comparison of neutrophil chemotactic factor release by human and rabbit alveolar macrophages in response to tannin exposure. J Lab Clin Med (1995) 0.75
A gene complex mediating cyst wall assembly and integrity in Pneumocystis carinii. J Eukaryot Microbiol (2001) 0.75
Characterization of the Cdc25 phosphatase in Pneumocystis carinii. J Eukaryot Microbiol (1999) 0.75
Laboratory diagnosis of Pneumocystis carinii infections by PCR directed to genes encoding for mitochondrial 5S and 28S ribosomal RNA. Diagn Microbiol Infect Dis (1999) 0.75
Role of nuclear factor-kappa B in the activation of alveolar macrophages by fungal beta-glucans. J Eukaryot Microbiol (2001) 0.75
Phosphatidylinositol kinase regulation of airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol (2000) 0.75